Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia

Vaccine

Volumn 35, Issue 7, 2017, Pages 1055-1063

  Sundaram, Neisha ^a   Chen, Cynthia ^a   Yoong, Joanne ^a   Luvsan, Munkh Erdene ^b   Fox, Kimberley ^c,i   Sarankhuu, Amarzaya ^d   La Vincente, Sophie ^e,f   Jit, Mark ^g,h  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b MONGOLIAN NATIONAL UNIVERSITY OF MEDICAL SCIENCES   (Mongolia)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d Ministry of Health and Sports   (Mongolia)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g PUBLIC HEALTH ENGLAND   (United Kingdom)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

ⁱ CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Budget impact; Cost effectiveness; Mongolia; PCV13; Pneumococcal conjugate vaccine; Vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; VACCINE;

ACUTE OTITIS MEDIA; ARTICLE; BUDGET; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEALTH CARE SYSTEM; HOSPITALIZATION; HUMAN; MENINGITIS; MONGOLIA; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; VACCINATION; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; IMMUNIZATION; IMMUNOLOGY; INFANT; MALE; MASS IMMUNIZATION; MICROBIOLOGY; PATHOGENICITY; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; STATISTICAL MODEL; STREPTOCOCCUS PNEUMONIAE;

CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INFANT; MALE; MASS VACCINATION; MODELS, STATISTICAL; MONGOLIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; QUALITY-ADJUSTED LIFE YEARS; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 85009809707     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.12.070     Document Type: Article

References (49)

1. [1] World Health Organization, Pneumococcal vaccines WHO position paper, 2012. Wkly Epidemiol Rec 87 (2012), 129–144.
2. [2] Center for Health Development, Health Indicators, 2014. 2014, Center for Health Development, Ulaanbaatar < http://www.chd.mohs.mn/images/pdf/sma/2015/eruul_mendiin_uzuulelt_2014_angli_1.pdf> [accessed 25/04/2016].
3. [3] Altangerel E. Air pollution is endangering children's health in Mongolia. 22 February 2016. Ulaanbaatar, Mongolia: UNICEF < http://www.unicef.org/health/mongolia_90290.html> [accessed 27/04/2016].
4. [4] Surenjav, E., Sovd, T., Yoshida, Y., Yamamoto, E., Reyer, J.A., Hamajima, N., Trends in amenable mortality rate in the Mongolian population, 2007–2014. Nagoya J Med Sci 78 (2016), 55–68.
5. [5] Rudan, I., O'Brien, K.L., Nair, H., Liu, L., Theodoratou, E., Qazi, S., et al. Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. J Glob Health, 3, 2013, 010401.
6. [6] Scott, S., Altanseseg, D., Sodbayer, D., Nymadawa, P., Bulgan, D., Mendsaikhan, J., et al. Impact of Haemophilus influenzae Type b conjugate vaccine in Mongolia: prospective population-based surveillance, 2002–2010. J Pediatr 163 (2013), S8–S11.
7. [7] Gavi The Vaccine Alliance. Mongolia proposals, reports & plans; Proposal for NVS – PCV support: Mongolia < http://www.gavi.org/country/mongolia/documents/#approvedproposal> [accessed 04/05/2016].
8. [8] Gavi The Vaccine Alliance. Transition process < http://www.gavi.org/support/apply/graduating-countries/> [accessed 03/05/2016].
9. [9] Centers for Disease Control and Prevention, Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease–United States, 1998–2003. MMWR Morb Mortal Wkly Rep 54 (2005), 893–897.
10. [10] Miller, E., Andrews, N.J., Waight, P.A., Slack, M.P., George, R.C., Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 11 (2011), 760–768.
11. [11] World Bank. Inflation, consumer prices (annual %), Mongolia. < http://data.worldbank.org/indicator/FP.CPI.TOTL.ZG> [accessed 3/10/2015].
12. [12] Tan, Torres.-Edejer T., Making choices in health: WHO guide to cost-effectiveness. 2003, World Health Organization, Geneva.
13. [13] World Health Organization. Mongolia life tables, life expectancy. Global Health Observatory Data Repository; 2011.
14. [14] Ministry of Health Mongolia. WHO/UNICEF Joint reporting form on immunization for the period January–December, 2013; 2014.
15. [15] Gavi The Vaccine Alliance. Supply agreements, Third AMC supply agreements < http://www.gavi.org/funding/pneumococcal-amc/manufacturers/supply-agreements/> [accessed 3/10/2015].
16. [16] UNICEF Supply Division. 2014–2018 Immunization forecast overview. Recommended budget prices for 2014; 2013.
17. [17] National Center for Communicable Diseases, Comprehensive multi-year plan for immunization of Mongolia 2011–2015. 2011, Ministry of Health, Mongolia.
18. [18] Klugman, K.P., Madhi, S.A., Huebner, R.E., Kohberger, R., Mbelle, N., Pierce, N., A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 349 (2003), 1341–1348.
19. [19] Davaalkham, J., Unenchimeg, P., Baigalmaa, C., Oyunbileg, B., Tsuchiya, K., Hachiya, A., et al. High-risk status of HIV-1 infection in the very low epidemic country, Mongolia, 2007. Int J STD AIDS 20 (2009), 391–394.
20. [20] Cutts, F.T., Zaman, S.M.A., Enwere, G.y., Jaffar, S., Levine, O.S., Okoko, J.B., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365 (2005), 1139–1146.
21. [21] Kaplan, S.L., Barson, W.J., Lin, P.L., Romero, J.R., Bradley, J.S., Tan, T.Q., et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 32 (2013), 203–207.
22. [22] Andrews, N.J., Waight, P.A., Burbidge, P., Pearce, E., Roalfe, L., Zancolli, M., et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis 14 (2014), 839–846.
23. [23] Johnson, H.L., Deloria-Knoll, M., Levine, O.S., Stoszek, S.K., Freimanis, H.L., Reithinger, R., et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med, 7, 2010.
24. [24] Tregnaghi, M.W., Saez-Llorens, X., Lopez, P., Abate, H., Smith, E., Posleman, A., et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med, 11, 2014, e1001657.
25. [25] Choi, Y.H., Jit, M., Gay, N., Andrews, N., Waight, P., Melegaro, A., et al. 7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement?. PLoS ONE, 6, 2011, e26190.
26. [26] Factor, S.H., LaClaire, L., Bronsdon, M., Suleymanova, F., Altynbaeva, G., Kadirov, B.A., et al. Streptococcus pneumoniae and Haemophilus influenzae type B Carriage, Central Asia. Emerg Infect Dis 11 (2005), 1476–1479.
27. [27] World Health Organization. Letter from EPI coordinator: estimates of severe illness cases and deaths in children from one month to less than five years of age due to Streptococcus pneumoniae in Mongolia; 2009.
28. [28] Capeding, M.R., Bravo, L., Santos, J., Kilgore, P.E., Kim, S.A., Balter, I., et al. Prospective surveillance study of invasive pneumococcal disease among urban children in the Philippines. Pediatr Infect Dis J, 32, 2013 p. e383–e9.
29. [29] Hasan, R., Rhodes, J., Thamthitiwat, S., Olsen, S.J., Prapasiri, P., Naorat, S., et al. Incidence and etiology of acute lower respiratory tract infections in hospitalized children younger than 5 years in rural Thailand. Pediatr Infect Dis J 33 (2014), e45–e52.
30. [30] Monasta, L., Ronfani, L., Marchetti, F., Montico, M., Vecchi Brumatti, L., Bavcar, A., et al. Burden of disease caused by otitis media: systematic review and global estimates. PLoS ONE, 7, 2012, e36226.
31. [31] National Statistics Office. UNICEF. “Multiple Indicator Cluster Survey 2010” Summary Report. Ulaanbaatar, Mongolia; 2011.
32. [32] Academy of Preventive Medicine [Kazakhstan], Macro International Inc., Kazakhstan Demographic and Health Survey 1999. Calverton, Maryland: Academy of Preventive Medicine and Macro International Inc.; 1999.
33. [33] National Statistical Office of Mongolia, Statistical Yearbook – 2012. 2013, National Statistical Office, Ulaanbaatar.
34. [34] World Bank. World Development Indicators, GDP per capita (current US$) for Mongolia < http://data.worldbank.org/data-catalog/world-development-indicators> [accessed 3/11/2014].
35. [35] World Health Organization. Global Health Expenditure Database < http://apps.who.int/nha/database/Select/Indicators/en> [accessed 3/10/2015].
36. [36] Mathers, C.D., Lopez, A.D., Murray, C.J.L., The burden of disease and mortality by condition: data, methods, and results for 2001. Lopez, A.D., Mathers, C.D., Ezzati, M., Jamison, D.T., Murray, C.J.L., (eds.) Global burden of disease and risk factors, 2006, World Bank, Washington (DC).
37. [37] Edmond, K., Clark, A., Korczak, V.S., Sanderson, C., Griffiths, U.K., Rudan, I., Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 10 (2010), 317–328.
38. [38] Waight, P.A., Andrews, N.J., Ladhani, N.J., Sheppard, C.L., Slack, M.P., Miller, E., Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis, 15, 2015, 629.
39. [39] Rodenburg, G.D., de Greeff, S.C., Jansen, A.G., de Melker, H.E., Schouls, L.M., Hak, E., et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, The Netherlands. Emerg Infect Dis 16 (2010), 816–823.
40. [40] Pan American Health Organization. Expanded program of immunization vaccines prices for year 2014 – Amendment I. PAHO Revolving Fund < http://www.paho.org/hq/index.php?option=com_content&view=article&id=1864&Itemid=40713&lang=en> [accessed 3/10/2015].
41. [41] Griffiths, U.K., Clark, A., Hajjeh, R., Cost-effectiveness of Haemophilus influenzae type b conjugate vaccine in low- and middle-income countries: regional analysis and assessment of major determinants. J Pediatr, 163, 2013 S50-S9.
42. [42] World Bank. GNI per capita for Mongolia, Atlas method (current US$) < http://data.worldbank.org/indicator/NY.GNP.PCAP.CD> [accessed 3/10/2015].
43. [43] O'Brien, K.L., Wolfson, L.J., Watt, J.P., Henkle, E., Deloria-Knoll, M., McCall, N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374 (2009), 893–902.
44. [44] Ochalek J, Lomas J, Claxton K. Cost per DALY averted thresholds for low- and middle-income countries: evidence from cross country data. CHE Research Paper 122. York: University of York; 2015.
45. [45] Kim, S.Y., Sweet, S., Slichter, D., Goldie, S.J., Health and economic impact of rotavirus vaccination in GAVI-eligible countries. BMC Public Health, 10, 2010, 253.
46. [46] Goldie, S.J., O'Shea, M., Campos, N.G., Diaz, M., Sweet, S., Kim, S.Y., Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 26 (2008), 4080–4093.
47. [47] Sinha, A., Levine, O., Knoll, M.D., Muhib, F., Lieu, T.A., Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 369 (2007), 389–396.
48. [48] Conklin, L., Loo, J.D., Kirk, J., Fleming-Dutra, K.E., Deloria Knoll, M., Park, D.E., et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. Pediatr Infect Dis J 33:Suppl 2 (2014), S109–S118.
49. [49] Whitney, C.G., Goldblatt, D., O'Brien, K.L., Dosing schedules for pneumococcal conjugate vaccine: considerations for policy makers. Pediatr Infect Dis J 33:Suppl 2 (2014), S172–S181.